Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Pasithea Therapeutics Corp. KTTA

Healthcare  —  Biotechnology
0.50 (0.01) (1.96%) as of 25 Sep
Market cap
$17.2M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Pasithea Therapeutics Corp. (KTTA) Business Profile

Updated before January 2025

Company Overview

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotechnology company focused on the research, development, and commercialization of innovative medical treatments. Founded in 2020, the company is headquartered in Miami Beach, Florida, and operates with a mission to address unmet medical needs in the fields of psychiatry, neurology, and other central nervous system (CNS) disorders. Pasithea Therapeutics was co-founded by Dr. Tiago Reis Marques, a renowned neuroscientist, and Dr. Lawrence Steinman, a distinguished immunologist and entrepreneur. The company is led by a team of experienced professionals, including Dr. Reis Marques as the Chief Executive Officer and Dr. Steinman as the Chairman of the Board.

Core Business Segments

Pasithea Therapeutics operates in two primary business segments:

1. Psychiatric and Neurological Treatments

The company focuses on developing therapies for mental health conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD). Its flagship product is ketamine-based therapy, which has shown promise in treating treatment-resistant depression. Pasithea offers these therapies through partnerships with clinics and healthcare providers, ensuring accessibility to patients in need.

2. Drug Development

Pasithea is actively engaged in the research and development of novel drugs targeting CNS disorders. The company leverages cutting-edge scientific research to create innovative treatments for conditions such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. This segment represents a significant growth opportunity for the company as it aims to bring new therapies to market.

Business Model

Pasithea Therapeutics employs a hybrid business model that integrates service delivery and drug development. The company generates revenue through:

  • Clinical Services: By partnering with healthcare providers, Pasithea offers ketamine-based therapies and other psychiatric treatments to patients. These services are provided on a fee-for-service basis.
  • Research and Development: Pasithea invests heavily in R&D to develop proprietary drugs. Revenue from this segment is expected to come from licensing agreements, partnerships with pharmaceutical companies, and eventual product sales.

This dual approach allows the company to address immediate patient needs while building a pipeline of innovative therapies for long-term growth.

Strategic Direction

Pasithea Therapeutics has outlined a clear strategic vision for its future:

  • Expansion of Clinical Services: The company plans to increase its network of partner clinics and expand the availability of its ketamine-based therapies to more regions.
  • Advancement of Drug Pipeline: Pasithea is committed to accelerating the development of its CNS drug candidates, with a focus on achieving key clinical milestones.
  • Sustainability Goals: The company aims to adopt environmentally sustainable practices in its operations and research activities.
  • Exploration of New Therapeutic Areas: Pasithea is exploring opportunities to expand its portfolio into other therapeutic areas, such as oncology and autoimmune diseases.

Competitive Landscape

Pasithea Therapeutics operates in a highly competitive market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Johnson & Johnson: Through its Spravato (esketamine) product, J&J is a major player in the ketamine-based therapy market.
  • MindMed: A biotech company focused on psychedelic-based therapies for mental health conditions.
  • COMPASS Pathways: Known for its psilocybin therapy for treatment-resistant depression.
  • Biogen: A leader in CNS drug development, particularly for Alzheimer’s and multiple sclerosis.

Despite the competition, Pasithea differentiates itself through its dual focus on clinical services and drug development, as well as its emphasis on scientific innovation.

Risk Factors

Investors and stakeholders should be aware of the following risks associated with Pasithea Therapeutics:

  • Regulatory Challenges: The company’s therapies and drug candidates are subject to stringent regulatory approval processes, which can be time-consuming and costly.
  • Market Dependence: Pasithea’s reliance on ketamine-based therapies exposes it to market fluctuations and changes in public perception of ketamine treatments.
  • Supply Chain Disruptions: The company’s operations could be impacted by disruptions in the supply of raw materials and components needed for drug development.
  • Competition: Intense competition in the biotech and pharmaceutical sectors could limit Pasithea’s market share and profitability.

Recent Developments

Pasithea Therapeutics has made significant strides in recent months:

  • Clinical Trials: The company initiated Phase I clinical trials for its lead CNS drug candidate, marking a major milestone in its R&D efforts.
  • Partnerships: Pasithea entered into a strategic partnership with a leading healthcare provider to expand its ketamine therapy services.
  • Corporate Strategy: The company announced plans to establish a dedicated research facility to accelerate drug development.
  • Global Developments: The ongoing COVID-19 pandemic has highlighted the importance of mental health, increasing demand for Pasithea’s psychiatric treatments.

Investment Considerations

Strengths:

  • Strong leadership team with expertise in neuroscience and immunology.
  • Dual focus on clinical services and drug development, providing diversified revenue streams.
  • Innovative approach to addressing unmet medical needs in CNS disorders.
  • Growing demand for mental health treatments.

Risks:

  • High R&D costs and long timelines for drug development.
  • Dependence on regulatory approvals for new therapies.
  • Competitive pressures from established and emerging players.

Conclusion

Pasithea Therapeutics Corp. is a promising player in the biotechnology sector, with a unique focus on psychiatric and neurological treatments. The company’s dual business model, innovative drug pipeline, and commitment to addressing unmet medical needs position it for long-term growth. While challenges such as regulatory hurdles and competition remain, Pasithea’s strategic direction and recent developments indicate a bright future for the company.